A method of treating anxiety in a subject having a mutation in the lynx2 gene and suffering from anxiety, includes administering to the subject an effective amount of a nicotinic blocker and/or an effective amount of a selective antagonist of the nicotinic acetylcholine receptor alpha-7 (nAChR α7) subunit.